Results 21 to 30 of about 3,791 (213)

Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study. [PDF]

EJNMMI Res
peptide receptor radionuclide therapy with 177Lu-DOTATATE has become an established second-line treatment for patients with advanced small intestine neuroendocrine tumors (siNET).
Megherbi I, Hoog C, Perrier M, Brixi H, Cadiot G, Hoeffel-Fornes C, Morland D.   +6 more
europepmc   +2 more sources

Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): multicentre phase II study. [PDF]

Br J Surg
Background Resection of non-functioning pancreatic neuroendocrine tumours (NF-PanNETs) is curative in most patients. The potential benefits of neoadjuvant treatments have, however, never been explored.
Partelli S, Landoni L, Bartolomei M, Zerbi A, Grana CM, Boggi U, Butturini G, Casadei R, Salvia R, Falconi M.   +9 more
europepmc   +2 more sources

Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects

World Journal of Nuclear Medicine, 2021
177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) alone has lesser potential in the clinical setting of neuroendocrine tumor (NET) with large bulky disease and nonhomogeneous somatostatin receptors (SSTR) distribution, owing to lower energy ...
Rahul Parghane, Arpit Mitra, Trupti Bannore, Sutapa Rakshit, Sharmila Banerjee, Sandip Basu   +5 more
doaj   +1 more source

A method to prevail false positive responses due to excess cations and viscous nature of Radiopharmaceuticals in Limulus Amebocyte Lysate Gel Clot test [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2022
Objective(s): Bacterial endotoxin test (BET) for detection and quantification of endotoxin in radiopharmaceuticals (RPs), used for therapy or diagnosis, is prerequisite to administration in patients.
Arpit Mitra, Sangita Lad, Sudeep Sahu, Savita Kulkarni   +3 more
doaj   +1 more source

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma

Frontiers in Endocrinology, 2021
BackgroundLutetium 177 (177Lu) - DOTATATE is a form of peptide receptor radionuclide therapy (PRRT) utilized in the treatment of neuroendocrine tumors. Data on 177Lu-DOTATATE-induced thyroid dysfunction is limited.Case DescriptionA 29-year-old male with ...
Sriram Gubbi, Mohammad Al-Jundi, Jaydira Del Rivero, Abhishek Jha, Marianne Knue, Joy Zou, Baris Turkbey, Jorge Amilcar Carrasquillo, Emily Lin, Karel Pacak, Joanna Klubo-Gwiezdzinska, Frank I-Kai Lin   +11 more
doaj   +1 more source

Predicting [177Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [68Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling

EJNMMI Physics, 2023
Background Prediction of [177Lu]Lu-HA-DOTATATE kidney and tumor uptake based on diagnostic [68Ga]Ga-HA-DOTATATE imaging would be a crucial step for precision dosing of [177Lu]Lu-HA-DOTATATE.
Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Marcel P. M. Stokkel, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx   +6 more
doaj   +1 more source

177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience

JCO Global Oncology, 2021
PURPOSETo compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Swayamjeet Satapathy, Bhagwant R. Mittal, Ashwani Sood, Apurva Sood, Rakesh Kapoor, Rajesh Gupta, Divya Khosla   +6 more
doaj   +1 more source

Phase II Study of ¹⁷⁷Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. [PDF]

J Clin Oncol
Purpose: 177Lu-DOTATATE is a somatostatin receptor (SSTR)-targeting radiopharmaceutical that shows promise for treating metastatic pheochromocytomas/paragangliomas (PPGLs), a rare SSTR-expressing tumor. Methods: In the first stage of this two-stage Simon
Lin FI, Del Rivero J, Carrasquillo JA, Jha A, Zou J, Shamis I, Talvacchio S, Turkbey B, Huang EP, Shih J, Klubo-Gwiezdzinska J, Mena E, Lindenberg L, Teng Y, Escorcia FE, Chen C, Herscovitch P, Millo C, Choyke PL, Pacak K.   +19 more
europepmc   +2 more sources

Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland

BMC Cancer, 2021
Background Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogenous group of tumors. Findings from the phase III NETTER-1 trial showed that treatment of unresectable/metastatic progressive gastrointestinal (GI) NETs with 177Lu ...
J. Smith-Palmer, O. R. Leeuwenkamp, J. Virk, N. Reed   +3 more
doaj   +1 more source

Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With 177Lu-DOTATATE: A Case Report

Frontiers in Endocrinology, 2021
IntroductionPrimary cardiac paragangliomas are rare tumors. Metastatic disease is even rarer. Surgical management is technically challenging, and sometimes even impossible.
Alexis Huot Daneault, Mélanie Desaulniers, Jean-Mathieu Beauregard, Alexis Beaulieu, Frédéric Arsenault, Geneviève April, Éric Turcotte, François-Alexandre Buteau   +7 more
doaj   +1 more source